Clinical Research

 

The Duke Division of Hematology is actively involved in clinical research that translates to advances and improvements in clinical care for patients with benign and malignant blood-related disorders.

Clinical research is being conducted in the following areas:

Current Clinical Trials

Myeloproliferate Neoplasms

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
ClinicalTrials.gov Identifier: NCT01259856
Principal Investigator: Murat Arcasoy, MD  
Contact: Murat Arcasoy, MD, 919-668-6309, arcas001@mc.duke.edu

Correlative Biomarker Study in Patients With Myeloproliferative Disorders
ClinicalTrials.gov Identifier: NCT00665067
Principal Investigator: Murat Arcasoy, MD   
Contact: Murat Arcasoy, MD    919-668-6309    arcas001@mc.duke.edu  

Apheresis Program
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

ClinicalTrials.gov Identifier: NCT01554514
Principal Investigator: Ara Metjian, MD
Contact: Betty H Thames, RN, BSN    919-681-9564    elizabeth.thames@duke.edu     

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

ClinicalTrials.gov Identifier: NCT02222545
Principal Investigator:
Contact: Angela Braswell (Pager) 970-6134

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)

ClinicalTrials.gov Identifier: NCT02553317
Principal Investigator:
Contact: Kristine Byrne 919-681-2668

Hemostasis and Thrombosis

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome (APS)

ClinicalTrials.gov Identifier: NCT00482794
Principal Investigator: Thomas L. Ortel, MD, PhD  
Contact: Thomas L. Ortel, MD, PhD, 919-684-5350 - thomas.ortel@duke.edu 

EINSTEIN Junior Phase III: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

ClinicalTrials.gov Identifier: NCT02234843
Principal Investigator: 
Contact: Shelia Lambert-Adams 919-970-0654

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)

ClinicalTrials.gov Identifier: NCT02111564
Principal Investigator: Carmelo Graffignino/Thomas Ortel
Contact: Betty Thames - 970-0331

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

ClinicalTrials.gov Identifier: NCT02610127
Principal Investigator: 
Contact: Kristen Mcgill 919-681-3565

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

ClinicalTrials.gov Identifier: NCT02303431
Principal Investigator:
Contact: Kristine Byrne 919-681-2668

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

ClinicalTrials.gov Identifier: NCT02427217
​Principal Investigator:

Sickle Cell Disease

ClinicalTrials.gov Identifier: NCT01788631
Principal Investigator: Marilyn J Telen, MD
Contact: Marilyn Telen, MD  - 919-684-5378 - marilyn.telen@dm.duke.edu     
 
ClinicalTrials.gov Identifier: NCT02179177
Principal Investigator: Nirmish Shah, MD
Contact: Sheila Lambert-Adams 970-0654

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

ClinicalTrials.gov Identifier: NCT02187003
Principal Investigator:
Contact: Angela Braswell 919-970-6134, Marilyn Telen, MD 919-684-5378 marilyn.telen@dm.duke.edu